The lastest clinical trails of Ovary cancer
- سال انتشار: 1403
- محل انتشار: دومین کنگره بین المللی کنسرژنومیکس
- کد COI اختصاصی: ICGCS02_332
- زبان مقاله: انگلیسی
- تعداد مشاهده: 78
نویسندگان
Department of Cellular and Molecular Biology, Najafabad Branch, Islamic Azad University, Isfahan, Iran
Shaghayegh Ataei Hossein Abadi
Department of Cellular and Molecular Biology, Najafabad Branch, Islamic Azad University, Isfahan, Iran
Department of Cellular and Molecular Biology, Najafabad Branch, Islamic Azad University, Isfahan, Iran
Department of Cellular and Molecular Biology, Najafabad Branch, Islamic Azad University, Isfahan, Iran
چکیده
Ovarian cancer(OC) is the ۱۱th most common cancer among women it's the ۵th leading cause of cancer-related mortality.OC is often diagnosed late; when the cancer has metastasized and is in the malignant stage with only ۱۵% of cases identified during early and localized phases. Current Screening methods to detect OC include; Pelvic examinations, transvaginal ultrasound, cancer antigen assessment(CA-۱۲۵), blood test, CT scan, and MRI scan. Methods: This review examines recent clinical studies on patients with ovarian cancer using articles published in Google Scholar between ۲۰۲۱ and ۲۰۲۴ using keywords such as ovarian cancer, chemotherapy, platinum-resistant, platinum-sensitive, surgery, and Radiotherapy. Results: After the diagnosis of the disease, the most primary and standard treatment currently approach involves a combination of surgical intervention, especially cell reduction, followed by chemotherapy. Although, according to the level of cancer and its spread in the body, additional methods such as radiotherapy and target therapy may be employed, and their treatment process is mentioned below in this article. Hormone therapy is commonly used to treat breast cancer but rarely used to treat specific OC types such as Granulosa cell tumors and certain slow-growing epithelial variants. About ۷۰% of ovarian cancer patients experience relapse post-surgery leading to a poor prognosis, so they need an alternative line of treatment, which often includes a chemotherapy diet based on platinum. However, specialists categorized the patients' reaction to the chemotherapy as either;platinum-sensitive(PS) or platinum-resistant(PR). It depends on the progression of the disease at different times after completion of platinum-based chemotherapy. For PS patients; treatment is alternative chemotherapy drugs such as Paciltaxed, liposomal, doxorubicin and gemcitabine are commonly used. In contrast PR patients, it's unlikely that the doctors will have used carboplatin again; The common and standard way is that they may suggest one or more of the following regimen: Paclitaxel alone(usually a weekly treatment), liposomal doxorubicin, gemcitabine, In cisplatin In or other agents. Target therapy and palliative radiotherapy(it can used for any part of the body where the cancer is causing problems) Can used as a side treatment for OC platinum-resistant. Target therapy may be administered alone or in conjunction with chemotherapy by drugs such as bevacizumab, olaparib,niraparib and Polymerase inhibitors (DNA-ribose). Conclusion: In this article, treatment strategies for significant survival and focusing on the chemotherapy drugs used and their performance for both platinum-resistant and platinum-sensitive cases will be examined.کلیدواژه ها
Overian cancer,platinum-resistant,platinum-sensitive,chemotherapy,surgeryمقالات مرتبط جدید
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.